Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.61 | N/A | +176.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.61 | N/A | +176.44% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline advancements. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Nektar Therapeutics reported a strong EPS performance, significantly exceeding expectations, which indicates effective cost management or operational efficiencies. However, the stock declined slightly by 0.47%, suggesting that investors may have been looking for additional revenue details or future guidance that was not provided. The lack of revenue figures and guidance may have contributed to the cautious market reaction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE MGMT INC DEL
Nov 2, 2020